FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
What happened
FDA reviewed Bliv's website in December 2025 and found it offered compounded semaglutide and tirzepatide drug products. The pictured labels showed "Bliv," which FDA says falsely suggests Bliv is the compounder when it is not. FDA therefore calls the products misbranded.
What FDA found
FDA says the website's claims and pictured labels falsely suggest Bliv is the compounder of the semaglutide and tirzepatide products, so the drugs are misbranded.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says advertising or promotion for a compounded drug is misbranded if it is false or misleading.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says introducing or delivering misbranded drugs into interstate commerce is prohibited.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA says receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]FDA says compounded drugs must meet the conditions in sections 503A or 503B to be exempt from certain requirements such as new drug approval.
FDCA §§ 503A, 503B [21 U.S.C. §§ 353a, 353b]FDA says a drug label that names a person without qualification represents that the person is the sole manufacturer, which is false if they are not.
21 CFR § 201.1(h)(2)
What FDA wants
Within 15 working days, provide a written response to FDA's Office of Compounding Quality and Compliance describing corrective steps, identifying the entities that produce the compounded products, providing sample labeling, and addressing or removing misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounders whose drugs are marketed by other brands
- websites that display drug labels naming a marketer or brand
This is a summary. Read the original letter on fda.gov.